Back to top
more

GENEDX HOLDINGS (WGS)

(Real Time Quote from BATS)

$125.45 USD

125.45
145,962

+4.08 (3.36%)

Updated Sep 17, 2025 12:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Here's Why Encompass Health Shares Are Attracting Investors Now

by Zacks Equity Research

EHC stock jumps 28.8% YTD as investors rally behind strong earnings beat, raised 2025 guidance and a growing national rehab hospital footprint.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.

Zacks Equity Research

Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates

by Zacks Equity Research

BKD continues to witness growth in revenue per available unit (RevPAR). It increases its EBITDA range for 2025.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now

by Zacks Equity Research

Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.

Zacks Equity Research

Here's Why You Should Add DexCom Stock to Your Portfolio Now

by Zacks Equity Research

DXCM continues to raise investor optimism due to its strong product portfolio.

Zacks Equity Research

Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up

by Zacks Equity Research

DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.

Zacks Equity Research

The Joint Misses Q1 Earnings Estimates on Rising Expenses

by Zacks Equity Research

JYNT expects to open 30-40 franchised clinics in 2025, down from 57 last year.

Zacks Equity Research

Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions

by Zacks Equity Research

ACHC continues to witness growth in patient days. It authorizes a share repurchase program of almost $300 million.

Zacks Equity Research

Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs

by Zacks Equity Research

MD anticipates adjusted EBITDA to be between $220 million and $240 million in 2025.

Zacks Equity Research

Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook

by Zacks Equity Research

SEM reiterates that earnings for 2025 are likely to be between $1.09 and $1.19 per share.

Zacks Equity Research

TDOC Q1 Loss Narrower Than Estimates on Strong Integrated Care Unit

by Zacks Equity Research

Teladoc Health expects Integrated Care members to be between 101 million and 103 million in 2025.

Zacks Equity Research

Best Momentum Stocks to Buy for May 5th

by Zacks Equity Research

WGS, EBMT and CBNK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2025.

Zacks Equity Research

New Strong Buy Stocks for May 5th

by Zacks Equity Research

WGS, NWG, HLF, CALM and ESEA have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2025.

Zacks Equity Research

GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 154.55% and 9.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GENEDX HOLDINGS (WGS) Upgraded to Buy: Here's Why

by Zacks Equity Research

GENEDX HOLDINGS (WGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?

by Zacks Equity Research

GeneDx is expected to have continued the strong 2024 momentum across all metrics in the first quarter of 2025.

Supriyo Bose headshot

Buy 3 Momentum Anomaly Stocks as Markets Rise Despite Tariff Threats

by Supriyo Bose

GME, WGS and APP are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

Zacks Equity Research

Zacks.com featured highlights DRDGOLD, GeneDx, EverQuote, HCI Group and Alibaba

by Zacks Equity Research

DRDGOLD, GeneDx, EverQuote, HCI Group and Alibaba have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Extreme Volatility

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are DRD, WGS, EVER, HCI, BABA.

Abhinab Dasgupta headshot

4 Healthcare Stocks to Buy as the Sector Stages a Comeback

by Abhinab Dasgupta

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies.

Zacks Equity Research

GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 250% and 3.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.